UNITED THERAPEUTICS Corp
Company Stats
- Market Cap
- $23.2B
- as of Sep 30, 2026
- Shares Outstanding
- 42.9M
- Free Float
- 85.4%
Income Statement
- Revenue
- $3.2B
- Operating Income
- $1.5B
- Net Income
- $1.3B
- EBITDA
- $1.6B
- Revenue Growth, 3Y
- 18.0%
- FCF Margin, 3Y Avg
- 34.1%
- FCF Margin, Worst Year
- 32.1%
Cash Flow
- Free Cash Flow
- $1.0B
- FCF Yield
- 4.5%
- Owner FCF Yield
- 3.8%
Balance Sheet
- Cash & Equivalents
- $1.6B
Returns & Capital
- Share Repurchases
- $1.0B
- Buyback Yield, 3Y Avg
- 2.9%
- SBC, 3Y Avg
- $110.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $3.2B | $1.0B | 32.7% |
| FY2024 | $2.9B | $1.1B | 37.6% |
| FY2023 | $2.3B | $747.6M | 32.1% |
| FY2022 | $1.9B | $663.7M | 34.3% |
| FY2021 | $1.7B | $477.4M | 28.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 10, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back